Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients - PubMed
6 hours ago
- #teclistamab
- #cytomegalovirus reactivation
- #multiple myeloma
- CMV reactivation occurs in approximately 22% of teclistamab-treated multiple myeloma patients, but most cases (89.5%) are asymptomatic and do not impact overall survival.
- Prior CMV reactivation is a significant predictor for subsequent reactivation, with an odds ratio of 3.34 in multivariable analysis.
- Prophylactic IVIG use is associated with improved survival in patients receiving teclistamab treatment.
- Symptomatic CMV reactivation is rare, with only four cases reported, three requiring treatment, and no end-organ damage observed.
- The findings support implementing risk-stratified CMV monitoring strategies for teclistamab-treated multiple myeloma patients.